Art. -Nr.: HY-162001

INX-315

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.75%
CAS. Nr.: 2745060-92-6
Formel: C₁₉H₂₁N₇O₃S
Molecular Weight:427.48

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

INX-315 Chemical Structure

CAS. Nr.: 2745060-92-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

CDK2^[1].

Alle CDK Isoform-spezifische Produkte anzeigen :

In Vitro

INX-315 (30-300 nM, 24 hours) inhibits cell cycle progression in OVCAR3 and MKN1 cells by reducing retinoblastoma protein (Rb) phosphorylation^[1].
INX-315 (0.3 nM to 10 μM, 6 days) inhibits cell proliferation in CCNE1-amplified ovarian carcinoma cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

OVCAR3 (CCNE1-amplified ovarian carcinoma cells) and MKN1 (gastric cancer cells)
Concentration:

30, 100, 300 nM
Incubation Time:

24 h
Result:

Reduced the phosphorylation level of Rb and the expression level of Cyclin A2.

Cell Viability Assay^[1]

Cell Line:

OVCAR-3 (CCNE1-amplified ovarian carcinoma cells)
Concentration:

0.3 nM to 10 μM
Incubation Time:

6 days
Result:

Decreased cell viability in a dose-dependent manner.

In Vivo

INX-315 (100 mg/kg, p.o., twice daily for 56 days) effectively inhibits tumor growth in a gastric adenocarcinoma BALB/c nude mouse model^[1].
INX-315 (100 mg/kg twice daily or 200 mg/kg once daily, i.p.) demonstrates significant tumor inhibition in the OVCAR3 ovarian cancer CDX model with good tolerance^[2].
INX-315 (100 mg/kg twice daily, i.p.) demonstrates significant antitumor activity in the GA0103 gastric cancer PDX model with good tolerance^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

OVCAR3 ovarian cancer CDX model constructed by injecting OVCAR3 ovarian cancer cell line into immunodeficient mice^[2]
Dosage:

100 or 200 mg/kg
Administration:

Intraperitoneal injection (i.p.), 100 mg/kg twice daily or 200 mg/kg once daily for up to 42 days
Result:

Resulted in tumor stasis (100 mg/kg twice daily), achieved 89% tumor growth inhibition (TGI), and did not cause significant weight loss (200 mg/kg once daily).

Animal Model:

GA0103 gastric cancer PDX model constructed by injecting patient-derived GA0103 gastric cancer tumor into immunodeficient mice^[2]
Dosage:

100 mg/kg
Administration:

Intraperitoneal injection (i.p.), twice daily for 56 days
Result:

Resulted in tumor stasis and did not cause significant weight loss.

Animal Model:

CCNE1-amplified gastric adenocarcinoma PDX (GA0103) in BALB/c nude mice model^[1]
Dosage:

25, 50, 100 mg/kg
Administration:

Oral gavage (p.o.), twice daily, for 56 days
Result:

inhibited the growth of tumor in a dose-dependent manner, with 100 mg/kg group showing tumor regression.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 2745060-92-6
Appearance Solid
Molecular Weight 427.48
Formel C₁₉H₂₁N₇O₃S
Color White to off-white
SMILES

O=C(NN1)C2(CCCCC2)N(C1=C3)C4=C3C=NC(NC5=CC=C(S(=O)(N)=O)C=C5)=N4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All Cell Proliferation/Viability AssayWBRT-PCRBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

NPJ Precis Oncol

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. [Abstract]

2025 Jul 7;9(1):223. PMID: 40624104

INX-315 purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Jul 7;9(1):223. [Abstract]

INX-315 (72 h) inhibited the cell growth of CDK2-knockdown PC3, ResA, and 22RV1 cells.

INX-315 purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Jul 7;9(1):223. [Abstract]

INX-315 (2 μM, 6 h) inhibited the mRNA expression of ASPM, CDC20, DLGAP5, and KIF18A in CDK2-knockdown PC3, ResA, and 22RV1 cells.
NPJ Breast Cancer

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. [Abstract]

2025 Dec 3;11(1):135. PMID: 41339342
EMBO J

WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer. [Abstract]

2025 Aug;44(15):4378-4405. PMID: 40551011

INX-315 purchased from MedChemExpress. Usage Cited in: EMBO J. 2025 Aug;44(15):4378-4405. [Abstract]

Wild-type hTERT-RPE1 FUCCI cells were synchronized in G2 with a CDK1 inhibitor for 18 h, treated for 8 h with 100 nM of the CDK2 inhibitor PF-06873600 (CDK2i), 500 nM, 1 µM, or 2 µM of the alternative CDK2 inhibitor INX-315 (CDK2i-2), or 5 µM of the pan-CDK inhibitor flavopiridol (panCDKi), or DMSO (–), and then analyzed by Western blotting for cell cycle markers.
Sci Signal

p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. [Abstract]

2025 Nov 25;18(914):eadv0415. PMID: 41289358
bioRxiv

A functional map of CDK-drug interactions at single amino acid resolution. [Abstract]

2025 Nov 3:2025.11.02.685764. PMID: 41279360
bioRxiv

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. [Abstract]

2024 Nov 15:2024.11.11.623139. PMID: 39605351

INX-315 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2024 Nov 15:2024.11.11.623139. [Abstract]

Continuous Palbociclib (1 μM) and fulvestrant (500 nM) treatment for 20 days significantly reduced resistant-cell growth compared to palbociclib discontinuation, fulvestrant alone, or fulvestrant plus INX-315 (100 nM).

INX-315 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2024 Nov 15:2024.11.11.623139. [Abstract]

Treatment with INX-315 (0.1 μM, 24 h) initially inhibited CDK2 or CDK4/6 activity within 1–2 h after drug treatment, but reactivation occurred regardless of cyclin E1 or A2 overexpression in MCF7 cells.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (233.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3393 mL

11.6965 mL

23.3929 mL

5 mM

0.4679 mL

2.3393 mL

4.6786 mL

10 mM

0.2339 mL

1.1696 mL

2.3393 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023 Dec 4. [Content Brief]

[2]. Trub A G, et al. INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers[J]. Cancer Research, 2023, 83(7_Supplement): 5994-5994.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3393 mL	11.6965 mL	23.3929 mL	58.4823 mL
	5 mM	0.4679 mL	2.3393 mL	4.6786 mL	11.6965 mL
	10 mM	0.2339 mL	1.1696 mL	2.3393 mL	5.8482 mL
	15 mM	0.1560 mL	0.7798 mL	1.5595 mL	3.8988 mL
	20 mM	0.1170 mL	0.5848 mL	1.1696 mL	2.9241 mL
	25 mM	0.0936 mL	0.4679 mL	0.9357 mL	2.3393 mL
	30 mM	0.0780 mL	0.3899 mL	0.7798 mL	1.9494 mL
	40 mM	0.0585 mL	0.2924 mL	0.5848 mL	1.4621 mL
	50 mM	0.0468 mL	0.2339 mL	0.4679 mL	1.1696 mL
	60 mM	0.0390 mL	0.1949 mL	0.3899 mL	0.9747 mL
	80 mM	0.0292 mL	0.1462 mL	0.2924 mL	0.7310 mL
	100 mM	0.0234 mL	0.1170 mL	0.2339 mL	0.5848 mL

Keywords

INX-315

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

INX-315

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) INX-315

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

INX-315

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) INX-315

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

INX-315 Related Classifications

HY-162001 Related Classifications